Lecture 3 Flashcards
(30 cards)
Digitalis
Used to treat dropsy (congestive heart failure)
Ma huang
Heart stimulant and for nasal and chest congestion
Target identification
Identification of biological components that are potentially drugable
Target validation
Determines whether interfering with the target is likely to have an impact on cancer growth
Target to hit
Large numbers of chemical and biological agents are screened to identify molecules that hit the target
Hit to lead
Hits are further tested to determine which bind the target with my specificity
Lead optimization
Refining the properties of the lead molecules to enhance potency and reduce side effects
Preclinical testing
Test for effectiveness of optimize lead
Clinical trials
Determines whether it improves patient outcomes
Phase 1
3 to 18 months
Evaluate safety, tolerability, PK and effects in healthy volunteers
Phase 2
1-3 years.
Assesses effectiveness, side effects and other safety features and forms a dosing strategy and several HUNDRED patients
Phase 3
2-6 years
Establishes efficacy and adverse effects from long-term uses and THOUSANDS of patients
Phase 4
Continuous
Monitoring of effects contraindications and interactions reported by MD and Pharm.D.
IND
Investigational new drug application
Before phase 1
NDA
New drug application
After phase 3 before phase 4
Lipitor
HMG CoA inhibitor
Cholesterol
Plavix
Antiplatelet
Thrombosis
Nexium
Proton pump inhibitor
Antiulcer
Norvasc
Calcium channel blocker.
Hypertension
What is out there and is there room for improvement?
Cure rather than alleviating symptoms the holy Grail.
Act on underlying pathophysiology. Greater efficacy.
New dosage form
Fewer side effects
Ideal target
Disease modifying or proven function
Known 3-D structure
Easy assay allowing high throughput screening
To be a target?
It has to be validated
Gene knockout
Removal of the gene that encodes for the biomolecule of interest
RNAi
Double-stranded RNA interfering with the expression of genes the sequences complementary to dsRNA